Tumour cell kinetics as a prognostic factor in squamous cell carcinoma of the cervix treated with radiotherapy.
OBJECTIVE
Proliferative rate and DNA ploidy status were evaluated by flow cytometry in cervical cancer patients, prior to radiotherapy, to assess their importance as prognostic factors to predict survival rates.


METHODS
Between 1987 and 1995, a total of 260 patients with squamous cell carcinoma (SCC) of the cervix, FIGO stages IB-IIIB were analysed. Tumour samples were incubated with bromodeoxyuridine (BrdUrd) in vitro to measure their total labelling index (totLI) and LI (totLI for diploid and anLI for aneuploid tumours). Proliferation was also assessed by S-phase fraction (SPF) analysis of the DNA profile. Patients had intracavitary therapy (three applications, each of 16 Gy to point A) and XRT of 40-50 Gy given over 4-5 weeks.


RESULTS
The cervical tumours were characterized by a high proliferation rate which varied within each clinical stage of disease. The totLI ranged from 1.1 to 33.1% with median value of 9.6% whilst the LI ranged from 1.1 to 37.1% with a median value of 10.9%. Univariate analysis identified patient's age (cut-offpoint < or = 50&greater; years) and to a lesser extent proliferation (cut-off point, median totLI=9.6%) as significant prognostic factors for 5-year survival. The median survival time for younger patients ( < or = 50 years) with tumours of low proliferation (totLI < or = 9.6%) tumours was 17.5 months compared with 56 months in the faster proliferating tumours (P=0.0354). In the older patient sub-group, proliferation rate had no influence on survival. The median LI value was not a useful parameter in survival. Cox multivariate analysis showed that patient age ( < or = 50 years) and low proliferation of the tumour cells (totLI < or = 9.6) were unfavourable prognostic factors for cervical cancers treated with radiotherapy. DNA ploidy was not significant in this series.


CONCLUSIONS
These data suggest that further improvements in therapy might be gained by selection of alternative treatments strategies such as neoadjuvant chemotherapy or radiation sensitizers in younger patients with more slowly proliferating tumours.
Gasińska
A
A
Laboratory of Radiation Biology, Centre of Oncology, Kraków, Poland.
Urbański
K
K
Jakubowicz
J
J
Klimek
M
M
Biesaga
B
B
Wilson
G D
GD
D000328:Adult; D000367:Age Factors; D000368:Aged; D000704:Analysis of Variance; D000782:Aneuploidy; D000963:Antimetabolites; D001918:Brachytherapy; D001973:Bromodeoxyuridine; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology* / Q000532:radiotherapy; D002453:Cell Cycle; D002455:Cell Division / Q000528:radiation effects; D004273:DNA, Neoplasm / Q000528:radiation effects; D004171:Diploidy; D005260:Female; D005434:Flow Cytometry; D005544:Forecasting; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D016016:Proportional Hazards Models; D011879:Radiotherapy Dosage; D016196:S Phase; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000235:genetics / Q000473:pathology* / Q000532:radiotherapy
D000963:Antimetabolites; D004273:DNA, Neoplasm; D001973:Bromodeoxyuridine